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OBJECTIVE — Vitamin K has a potentially beneﬁcial role in insulin resistance, but evidence
is limited in humans. We tested the hypothesis that vitamin K supplementation for 36 months
will improve insulin resistance in older men and women.
RESEARCH DESIGN AND METHODS — This was an ancillary study of a 36-month,
randomized, double-blind, controlled trial designed to assess the impact of supplementation
with 500 g/day phylloquinone on bone loss. Study participants were older nondiabetic men
and women (n  355; aged 60–80 years; 60% women). The primary outcome of this study was
insulin resistance as measured by homeostasis model assessment (HOMA-IR) at 36 months.
Fasting plasma insulin and glucose were examined as the secondary outcomes.
RESULTS — Theeffectof36-monthvitaminKsupplementationonHOMA-IRdifferedbysex
(sex  treatment interaction P  0.02). HOMA-IR was statistically signiﬁcantly lower at the
36-month visit among men in the supplement group versus the men in the control group (P 
0.01) after adjustment for baseline HOMA-IR, BMI, and body weight change. There were no
statisticallysigniﬁcantdifferencesinoutcomemeasuresbetweeninterventiongroupsinwomen.
CONCLUSIONS — VitaminKsupplementationfor36monthsatdosesattainableinthediet
may reduce progression of insulin resistance in older men.
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L
imitedevidencefromhumanandan-
imal studies suggests that vitamin K
may be inversely associated with in-
sulinresistance(1–4).Inanobservational
study, higher dietary and supplemental
vitamin K intakes were associated with
greater insulin sensitivity and better gly-
cemic status in a community-based co-
hort of men and women (3). In a small
metabolic study of young men (n  12),
short-term (1-week) vitamin K supple-
mentation improved the insulin re-
sponse after an oral glucose challenge
(2). Although these studies support a
potential novel role for vitamin K in in-
sulin resistance, the available human
data are limited. Furthermore, biological
mechanisms behind the association be-
tween vitamin K and insulin and glucose
metabolism are uncertain. Vitamin K and
vitamin K–dependent proteins (pro-
thrombin and protein S) have been iden-
tiﬁed in organs important for glucose and
insulinmetabolism,suchasliverandpan-
creas (5,6). However, the function of vi-
taminKisnotwellunderstoodbeyondits
role as an enzyme cofactor for -carbox-
ylationofcertainglutamicacidresiduesin
vitamin K–dependent proteins (7).
The objective of this study was to as-
sess the effect of vitamin K supplementa-
tion for 36 months on insulin resistance,
deﬁned as the homeostasis model assess-
ment of insulin resistance (HOMA-IR),
among older men and women in a ran-
domized, double-blind, controlled trial.
The primary end point for the original
trial was the 36-month change in bone
mineral density of the femoral neck. We
hypothesized that vitamin K supplemen-
tation at intakes attainable in the diet
would have beneﬁcial effects on insulin
resistance. As secondary objectives, we
alsoexaminedtheeffectofvitaminKsup-
plementation on fasting plasma insulin
and glucose concentrations.
RESEARCH DESIGN AND
METHODS— Men and postmeno-
pausal women, aged 60–80 years, were
recruited as part of a 36-month random-
ized, double-blind, controlled vitamin K
supplementation trial designed to test the
primary hypothesis that vitamin K sup-
plementation would reduce age-related
bonelossandvascularcalciﬁcation,asde-
scribed elsewhere (8). Exclusion criteria
included coronary heart disease, renal
disease or nephrolithiasis, liver disease,
osteoporosis, and use of medications
knowntoinﬂuencebonehealth.Diabetes
was not an exclusion criterion, and use of
insulin or oral hypoglycemic medications
was allowed. However, for the purpose of
the present study, we excluded subjects
with diabetes from the analysis. Diabetes
was deﬁned as fasting glucose 126
mg/dl and/or self-reported use of hypo-
glycemic drugs or insulin medication
during the study.
The subjects were advised to main-
tain their usual diets and to avoid taking
dietary supplements other than those
provided throughout the study. The
treatment group received 500 g/day
phylloquinone(vitaminK1),whichisap-
proximately ﬁve times the adequate in-
take for vitamin K (9), as part of an
effervescent multivitamin formulation.
The control group received the multivita-
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All study participants also received a sec-
ond daily effervescent tablet containing
600 mg elemental calcium in the form of
calcium carbonate and 10 g (400 IU) of
vitamin D in the form of cholecalciferol.
Detailed information on the supplements
is provided elsewhere (8).
Of the original 452 participants en-
rolled,355whodidnothavediabetescom-
pleted the study (Fig. 1). All participants
provided written informed consent, and
thisstudywasapprovedbytheinstitutional
review board at Tufts Medical Center.
Biochemical measurements
All blood samples were drawn between
7:00and10:00 A.M.afteraminimum10-h
fast. Dedicated aliquots of plasma and se-
rum were stored at 80°C and protected
from light until the time of analysis.
Plasma insulin was determined using Hu-
man Insulin Speciﬁc RIA kits (Linco Re-
search, St. Charles, MO). All assays were
done in duplicate, and the measurements
were repeated if the total coefﬁcient of
variation (CV) of the duplicates was
15%. The within-run CV of the sam-
ples was 6.4%. Plasma glucose was an-
alyzed using the enzymatic kinetic
(hexokinase-UV/NAD) method on an
Olympus AU400 instrument with
Olympus agents. The intra-assay CV
percent was 2.0% and the interassay CV
percent was 3.4%. HOMA-IR was calcu-
lated as (fasting plasma glucose [milli-
moles per liter]  fasting plasma insulin
[microunits per milliliter])/22.5 (10).
Plasma phylloquinone and the propor-
tionofosteocalcinthatisnotcarboxylated
(percent undercarboxylated osteocalcin)
are biochemical markers for vitamin K
status (11,12), and changes in these
markers were examined to assess the
overall efﬁcacy of the vitamin K supple-
mentation. Plasma concentrations of
phylloquinone were measured by re-
verse-phase high-performance liquid
chromatography (13). The total CVs for
the two control samples with average
phylloquinone results of 1.2 and 4.5
nmol/l were 7.4 and 8.0%, respectively.
Serum total and undercarboxylated os-
teocalcin were measured by radioimmu-
noassay,usingthemethodofGundberget
al. (11). The total CVs for the three con-
trol samples with an average total osteo-
calcin result of 6.4, 14.7, and 23.8 were
8.8, 8.9, and 7.6%, respectively. Because
vitamin K is a cofactor for carboxylation
of speciﬁc glutamate residues, lower per-
cent undercarboxylated osteocalcin indi-
cates high vitamin K status (11).
Other measurements
Total body fat was measured by whole-
body dual-energy X-ray absorptiometry
scan using a GE Lunar model Prodigy
scanner (Encore 2002 software, version
6.10.029). Leisure, household, and occu-
pationalactivitywasestimatedwithuseof
the Physical Activity Scale for the Elderly
questionnaire (14). Tobacco and alcohol
use was determined by questionnaire.
Height was measured with a stadiometer
and weight with a digital scale. BMI was
calculated as weight in kilograms divided
by the square of height in meters. Usual
dietary intakes over the year before entry
in the study were assessed using the Har-
vard food frequency questionnaire (15).
Information on adherence to the supple-
mentation (percent) was created on the
basis of self-reported pill count.
Statistical analysis
SASstatisticalsoftware(version9;SASin-
stitute, Cary, NC) was used for all statis-
tical analyses. Statistical signiﬁcance was
deﬁned as P  0.05.
The characteristics of the two study
treatment groups were compared at base-
line using Student’s t test and Fisher’s exact
test for continuous and categorical vari-
ables, respectively. The distributions of
HOMA-IR, fasting insulin, plasma phyllo-
quinone, and phylloquinone intake were
skewedtotheright;thus,weanalyzedthese
variables using the natural logarithm trans-
formation. To assess overall efﬁcacy of vita-
min K supplementation, we examined
changesinbiochemicalmeasuresofvitamin
K status (i.e., plasma phylloquinone and
percent undercarboxylated osteocalcin) be-
tweenbaselineandthe36-monthvisit.Stu-
dent’sttestwasusedtocomparechangesof
vitamin K status and other characteristics
between the two study groups.
The effects of vitamin K supplemen-
tation on HOMA-IR and fasting plasma in-
sulin and glucose concentrations were
assessed by using analysis of covariance at
the6-and36-monthvisits.Covariatesused
in the analysis were baseline outcome mea-
sures and BMI and weight change. We sub-
sequently repeated the analysis using the
36-month change in physical activity and
totalbodyfatasadditionalcovariates.There
Figure 1—Study sample selection.
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tremelyhighplasmafastinginsulinconcen-
tration(fastinginsulinof82.3U/ml).This
participant was removed from the
HOMA-IR and fasting insulin analysis, al-
though inclusion or exclusion of this
potential outlier did not signiﬁcantly
change the results. We also repeated
analyses with two sets of data excluding
participants with 85% adherence to
vitamin K supplement (n  66) or in-
cluding those with diabetes (n  46) to
assess the stability of the ﬁndings.
We tested for statistical interaction
between vitamin K intervention and sex.
Because we observed signiﬁcant inter-
actions between sex and treatment group
inHOMA-IRandplasmafastinginsulinat
the 36-month visit (HOMA-IR P  0.02;
insulin P  0.01), men and women were
analyzed separately. With our overall
sample size of 355 and signiﬁcant be-
tween-group difference in HOMA-IR of
0.44, with a between-group SD of 1.4,
there was an 82% chance that the hy-
pothesis of no supplement effect would
be rejected at the 0.05 level of signiﬁ-
cance. However, upon stratiﬁcation by
sex,thestatisticalpowerwasreducedto
44% in men and 62% in women.
To explore a possible explanation for
the observed sex interaction, we exam-
ined the associations between plasma
phylloquinone concentrations and BMI.
We calculated plasma triglyceride-
adjusted Pearson’s partial correlation co-
efﬁcients (Pearson’s partial r).
RESULTS— The baseline characteris-
tics are summarized in Table 1. Partici-
pant characteristics were comparable
betweenthetwotreatmentgroupsinboth
men and women, with the exception of
higher prevalence of overweight or obe-
sity among women in the vitamin
K–treated group.
In the vitamin K–treated group, 36-
month changes in plasma phylloquinone
and percent undercarboxylated osteocal-
cinweresigniﬁcantlydifferentfromthose
of the control group for both men and
women (P  0.001). The mean  SD 36-
month changes in plasma phylloquinone
concentrations for men and women re-
ceiving the vitamin K supplement were
1.4  2.5 and 2.3  2.8 nmol/l, respec-
tively, whereas the changes in the men
and women in the control group were
0.21.9and0.11.3nmol/l,respec-
tively. The 36-month changes in percent
undercarboxylated osteocalcin were
19.0  23.4% for men and 19.3 
20.5% for women in the treated group
and 0.4  17.7% for men and 2.3% 
21.2% for women in the control group.
HOMA-IR and plasma insulin con-
centrations were statistically signiﬁcantly
loweratthe36-monthvisitamongmenin
the supplement group versus men in the
control group after adjustment for base-
line HOMA-IR, BMI, and weight change
(Table 2). There was no signiﬁcant differ-
ence among men in HOMA-IR and
plasmainsulinatthe6-monthvisit.When
statistical analyses were repeated using
the 36-month change in physical activity
and percent body fat as additional covari-
ates,differencesamongmeninHOMA-IR
werestillstatisticallydifferent(P0.03),
whereas there was attenuation in differ-
ences in the plasma insulin (P  0.07).
When statistical analyses were restricted
to those with 85% adherence, similar
results were noted for 36-month changes
in HOMA-IR and plasma insulin among
men (vitamin K–treated group versus
control group: HOMA-IR, 0.11 [95%
CI0.40to0.19]vs.0.47[0.15to0.80],
P0.01;insulin,0.46[1.56to0.65]
vs.1.47[0.22to2.71],P0.03).Fasting
plasma glucose concentrations among
men did not differ between two study
groups at any time point. There were no
statistically signiﬁcant differences in
changes in HOMA-IR, fasting plasma
Table 1—Baseline characteristics in subjects included in the primary analysis
Men Women
Control Vitamin K P value Control Vitamin K P value
n 62 80 109 104
Age (years) 69.7  6.2 68.9  5.5 0.45 67.5  5.2 67.3  5.5 0.77
BMI (kg/m
2) 27.0  3.5 28.2  4.7 0.12 26.8  4.9 28.1  5.8 0.07
Overweight/obese (%)* 74 71 0.70 59 72 0.04
Total body fat (%) 36.0  9.8 37.8  8.8 0.29 38.3  9.2 36.7  9.8 0.23
Physical activity scale† 136  59 130  65 0.61 123  56 128  55 0.56
Current smoking (%) 8 3 0.24 3 8 0.13
Current alcohol drinking (%) 73 70 0.85 76 70 0.36
College or greater education (%) 58 68 0.29 47 45 0.89
Blood pressure medication use (%) 34 21 0.13 29 24 0.44
Statin use (%) 29 20 0.24 24 24 1.00
Undercarboxylated osteocalcin (%) 39.9  15.2 36.7  15.5 0.23 42.3  17.4 43.5  16.2 0.62
Plasma phylloquinone (nmol/l) 1.1  2 1.3  1.6 0.21 1.2  1.1 1.1  1.4 0.37
Phylloquinone intake (g/day) 168  114 176  118 0.68 180.8  113.6 170  96.7 0.81
Plasma glucose (mg/dl) 95.5  8.1 93.1  9 0.10 92  9.7 93.9  9.9 0.15
Plasma insulin (U/ml) 10.5  4.8 10.6  5.7 0.95 10.1  4.7 10.6  5.5 0.78
HOMA-IR 2.5  1.2 2.5  1.5 0.73 2.3  1.1 2.5  1.4 0.33
Discontinued taking calcium supplementation (%)‡ 8 6 0.75 12 11 0.83
Discontinued taking multivitamin supplements (%) 8 6 0.75 8 9 1.00
DataaremeansSDor%forcontinuousandcategoricalvariables,respectively.Forstatisticalanalysis,logarithmtransformationwasperformedforplasmainsulin,
HOMA-IR, plasma phylloquinone, and phylloquinone intakes. Phylloquinone intake included both dietary and supplemental sources of phylloquinone. *Deﬁned
as BMI 25 kg/m
2. †The physical activity scale was calculated on the basis of the questionnaire that captures leisure, household, and occupational activity (14).
Higher scores indicate more physically active condition. ‡Discontinued taking calcium and vitamin D supplementation.
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the vitamin K–treated groups and control
group. Repeating the analyses including
diabetic individuals did not affect our
ﬁndings (data not shown).
In analysis performed to examine a
possible reason for the discrepancy be-
tween ﬁndings for men and women, we
found that plasma phylloquinone con-
centrationswereinverselyassociatedwith
BMI in women, but not in men, after ad-
justment for plasma triglycerides (Pear-
son’s partial r  0.15, P  0.02). In
contrast, percent body fat was not corre-
lated with plasma phylloquinone concen-
trations in men or women. Among women
inourstudy,therewasasigniﬁcantincrease
in mean percent body fat of 0.6% over the
36 months (P  0.002), whereas body
weightdidnotchangesigniﬁcantly.Inmen,
meanbodyweightdecreasedby0.5kg(P
0.02) and body fat increased by 0.5% (P 
0.001), respectively. There were no statisti-
cally signiﬁcant changes in physical activity
for men or women.
CONCLUSIONS — The major ﬁnd-
ing of this study was that daily supplemen-
tation with 500 g of phylloquinone for 36
months had a protective effect on progres-
sion of insulin resistance in older men.
In an animal study, rats fed a low vi-
tamin K diet had impaired early insulin
response and subsequent increased insu-
linsecretionafterintravenousadministra-
tion of glucose (1). Higher vitamin K
intake was cross-sectionally associated
with reduced insulin resistance in both
men and women in the Framingham Off-
spring cohort (3). A metabolic study of
young men showed a signiﬁcant associa-
tion between vitamin K and post–glucose
challenge measures, but not fasting mea-
sures (2). In our study, a beneﬁcial effect
of vitamin K supplementation for 36
months was observed using fasting mea-
sures of insulin resistance. The effect of
this intervention on post–glucose chal-
lenge measures of insulin resistance was
not tested in our study.
Recent studies proposed that the un-
carboxylated form of osteocalcin, a vita-
min K–dependent bone protein, may
improve insulin sensitivity and increase
	-cell insulin secretion partially through
the enhancement of 	-cell proliferation,
energy expenditure, and adiponectin ex-
pression in mice (16,17). In our study,
men receiving vitamin K supplementa-
tion had less uncarboxylated osteocalcin
than the control group, which does not
supporttheﬁndingsoftheanimalstudies.
Alternatively,itisplausiblethatvitaminK
may improve insulin sensitivity through
suppression of inﬂammation. In vivo and
invitrostudieshaveshownthatvitaminK
reduced lipopolysaccharide-induced in-
ﬂammation(18,19).Morerecently,itwas
reported that biochemical and dietary
measures of vitamin K status were in-
versely associated with inﬂammatory
markers in an observational study (20).
The beneﬁcial effect of vitamin K on
insulin resistance was limited to men in
this study. However in a recent observa-
tional study, the inverse association be-
tween vitamin K intake and insulin
resistance was observed in men and
women (3). In a previous metabolic
study, only young men were studied (2),
and there are no other studies with which
to make a comparison. Although adjust-
ment of BMI in the statistical model did
not change our ﬁnding in women, one
potential explanation for this lack of pro-
tectiveeffectofvitaminKoninsulinresis-
tance in women is the role of adipose
tissue in modulating the response to vita-
min K supplementation. In our study,
overweight or obesity, which are major
determinants of insulin resistance (21,
22), wasmoreprevalent in women who re-
ceived vitamin K supplementation than in
those who did not. Furthermore, there was
an inverse association between plasma
phylloquinone concentrations and BMI in
the women, which is suggestive of an im-
paired response to vitamin K supplementa-
tion. It may be plausible that adipose tissue
Table 2—Changes for HOMA-IR, fasting plasma insulin, and glucose concentrations for vitamin K and non–vitamin K supplementation
Outcomes and
change Model
Men Women
Control Vitamin K
P
value Control Vitamin K
P
value
n 62 80 109 104
HOMA-IR
6 months Crude 0.02 (0.22 to 0.25) 0.06 (0.15 to 0.27) 0.77 0.03 (0.19 to 0.14) 0.04 (0.13 to 0.20) 0.61
6 months Adjusted 0.03 (0.21 to 0.27) 0.05 (0.16 to 0.26) 0.91 0.01 (0.17 to 0.15) 0.02 (0.14 to 0.19) 0.76
36 months Crude 0.35 (0.03 to 0.68) 0.09 (0.37 to 0.20) 0.05 0.16 (0.04 to 0.37) 0.31 (0.10 to 0.52) 0.32
36 months Adjusted 0.39 (0.09 to 0.69) 0.12 (0.38 to 0.15) 0.01 0.19 (0.00 to 0.38) 0.28 (0.09 to 0.48) 0.49
Plasma insulin
(U/ml)
6 months Crude 0.34 (1.27 to 0.59) 0.2 (1.02 to 0.63) 0.82 0.68 (1.34 to 0.03) 0.19 (0.86 to 0.48) 0.30
6 months Adjusted 0.29 (1.22 to 0.65) 0.23 (1.06 to 0.59) 0.93 0.60 (1.24 to 0.04) 0.28 (0.93 to 0.38) 0.49
36 months Crude 1.08 (0.15 to 2.30) 0.43 (1.51 to 0.64) 0.07 0.23 (0.50 to 0.97) 1.08 (0.33 to 1.83) 0.12
36 months Adjusted 1.16 (0.02 to 2.30) 0.49 (1.50 to 0.51) 0.04 0.37 (0.32 to 1.06) 0.94 (0.23 to 1.64) 0.26
Plasma glucose
(mg/dl)
6 months Crude 3.41 (1.79 to 5.04) 3.52 (2.09 to 4.96) 0.92 2.28 (0.80 to 3.75) 2.31 (0.80 to 3.82) 0.97
6 months Adjusted 3.70 (2.08 to 5.32) 3.30 (1.87 to 4.72) 0.72 2.43 (0.98 to 3.88) 2.16 (0.67 to 3.64) 0.80
36 months Crude 2.15 (0.20 to 4.10) 0.98 (0.75 to 2.72) 0.38 1.51 (0.04 to 3.05) 1.33 (0.24 to 2.91) 0.88
36 months Adjusted 2.57 (0.70 to 4.44) 0.65 (1.01 to 2.31) 0.14 1.68 (0.17 to 3.18) 1.16 (0.38 to 2.69) 0.64
Data are least-squares means (95% CI). Least-squares means are the mean changes in the outcomes when individual values covariates are held constant. Crude
analysiswasadjustedforthebaselineoutcomemeasure(HOMA-IR,plasmainsulin,orglucose).Adjustedanalysiscontrolledforbaselineoutcomemeasures,baseline
BMI, and either 6- or 36-month weight change.
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renderthevitaminKunavailableforperiph-
eral organs. In the absence of data on the
role of adipose tissue in vitamin K metabo-
lism, this suggestion is currently specula-
tive. Alternatively, it is plausible that our
study was statistically underpowered to de-
tect statistically signiﬁcant differences in
HOMA-IRinresponsetovitaminKsupple-
mentation among women.
The interpretation of these ﬁndings
is limited by several factors. First, this
study was based on the analyses of data
obtained from a study designed to deter-
mine the effect of vitamin K supplemen-
tationonchangesinbonemineraldensity
and vascular calciﬁcation in older men
andwomen.Ourﬁndingsmaynotberep-
resentative of the general population ow-
ing to the exclusion criteria of the parent
study, and measures presented in this
study were not necessarily obtained by
optimal techniques. We acknowledge
that use of the hyperinsulinemic-
euglycemic clamp would have provided a
more direct measure of insulin secretion
and sensitivity than HOMA-IR, which
only provides an indirect estimate of in-
sulinresistance.Likewise,ourassessment
of body composition was limited to BMI
andpercentbodyfatasmeasuredbydual-
energy X-ray absorptiometry and did not
provide information on regional adipos-
ity. We also had limited statistical power
to detect differences in HOMA-IR in re-
sponse to vitamin K supplementation,
which may explain the null ﬁndings in
women. Finally, most of our participants
were Caucasians; thus, our ﬁndings need
to be examined in other populations.
In summary, 36 months of vitamin K
supplementation had a beneﬁcial effect
on insulin resistance in older men but not
in older women. As the parent study was
not designed to test this hypothesis, these
ﬁndings need to be replicated in a study
designed speciﬁcally to test the hypothe-
sisthatvitaminKplaysaprotectiverolein
insulin resistance in older adults.
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